Antimycobacterial Activity of the Extract and Isolated Compounds From the Stem Bark of Zanthoxylum leprieurii Guill. and Perr.

Benson Oloya1,2, Jane Namukobe1, Matthias Heydenreich3, Willy Ssengooba4, Bernd Schmidt3 and Robert Byamukama1

Abstract
Zanthoxylum leprieurii Guill. and Perr. (Rutaceae) stem bark is used locally in Uganda for treating tuberculosis (TB) and cough-related infections. Lupeol (1), sesamin (2), trans-fagaramide (3), arnottianamide (4), (S)-marmesinin (5), and hesperidin (6) were isolated from the chloroform/methanol (1:1) extract of Z. leprieurii stem bark. Their structures were elucidated using spectroscopic techniques and by comparison with literature data. Furthermore, the extract and isolated compounds were subjected to antimycobacterial activity. The extract exhibited moderate activity against the susceptible (H37Rv) TB strain, but weak activity against the multidrug resistant (MDR)-TB strain with minimum inhibitory concentrations (MICs) of 586.0 and 1172.0 μg/mL, respectively.

Compound 3 (trans-fagaramide) showed significant antimycobacterial activity against the susceptible (H37Rv) TB strain (MIC 6 μg/mL), but moderate activity against the MDR-TB strain (MIC 12.2 μg/mL). Compounds 2, 5, 6, and 1 showed moderate activities against the susceptible (H37Rv) strain (MIC 24.4-98.0 μg/mL) and moderate to weak activities against the MDR-TB strain (MIC 24.4-195.0 μg/mL). This study reports for the first time the isolation of compounds 1 to 6 from the stem bark of Z. leprieurii. Trans-fagaramide (3) may present a vital template in pursuit of novel and highly effective TB drugs.

Keywords
Tuberculosis, Zanthoxylum leprieurii, antimycobacterial activity, trans-fagaramide, alkaloid

Received: April 23rd, 2021; Accepted: July 7th, 2021.

Introduction
Tuberculosis (TB) is a cause of ill-health for about 10 million people globally each year and is ranked among the leading 10 causes of death globally, as well as the main cause of death arising from a sole infectious agent, and ranked above human immunodeficiency virus/acquired immunodeficiency syndrome. Currently, Africa has the most significant burden of TB globally, with a prevalence of 226 cases per 100,000 individuals in relation to the global average of 130 cases per 100,000 individuals. In Uganda, the average TB prevalence is 200 cases per 100,000 people, which puts this country among the high TB-laden countries in the world.1

The rise of drug-resistant TB strains remains a public health danger and is among the primary reasons contributing to the increase of global incidence of TB.1 In 2019, World Health Organization (WHO) reported that there were about 500,000 new cases of TB which had developed resistance to rifampicin, and, of those, 78% had developed multidrug resistance (MDR-TB).1 Consequently, this necessitates exploring any existing avenues to develop novel and highly efficacious drugs for the treatment of TB.

Natural products have proved to be templates for novel drug development. They have several exciting biological activities and thus, they have been accorded significant consideration as possible sources of drugs for TB.2 One of the plants that needed to be evaluated for anti-TB agents is Z. leprieurii since its stem bark is being used in Uganda by the local communities to manage TB and other infections related to cough.3 Consequently, this study aimed to determine the constituents of the chloroform/methanol (1:1, v/v) extract of Z. leprieurii

1Department of Chemistry, Makerere University, Kampala, Uganda
2Department of Chemistry, Muni University, Arua, Uganda
3Institute of Chemistry, University of Potsdam, Potsdam, Germany
4Department of Microbiology, Makerere University, Kampala, Uganda

Corresponding Author:
Benson Oloya, Department of Chemistry, College of Natural Sciences, Makerere University, P.O. Box 7062, Kampala, Uganda.
Email: boloya@muni.ac.ug
stem bark and evaluate the in vitro anti-TB activities of the extract and the compounds isolated from it against both the susceptible (H37Rv) and MDR-TB strains.

Results and Discussion

Structures of Isolated Compounds

The spectroscopic data of the isolated compounds are presented in the supplemental material. Compounds 1, 2, 3, 4, 5, and 6 were isolated from the chloroform/methanol (1:1) extract of Z. leprieurii stem bark. Following detailed spectroscopic analyses and also, by comparison with literature data, the compounds were elucidated as lupeol (1),4,5 sesamin (2),6,7 trans-fagaramide (3),8,9 arnottianamide (4),10,11 (3)-marmesinin (5),12 and hesperidin (6).13 Figure 1 shows the molecular structures of all 6 isolated compounds. This is the first report of the isolation of these compounds from Z. leprieurii stem bark, although compounds 1 and 2 had been reported previously from its root bark.14 Also, it is the first report of the isolation of compound 5 from the family Rutaceae. Compounds 1, 2, 3, and 4 have also been reported from Z. gilletti and Z. heitzii15,16,17 which points to a close chemo-taxonomic relationship between these 3 Zanthoxylum species.

The chloroform/methanol (1:1) extract afforded a triterpene, a lignan, a coumarin, alkaloids, and a flavanone, as compared to a previous report where a methanol extract of Z. leprieurii stem bark afforded only acridone alkaloids.18 A chloroform/methanol (1:1, v/v) mixture, which is of medium polarity, was chosen for extraction because it has been reported that organic extractions made using such solvents are expected to be composed of phytochemicals like alkaloids, polyphenols, and terpenoids, having activity against microbes.19-21 Furthermore, such a solvent mixture can extract lipophilic constituents of the plant, which can easily permeate through the M. tuberculosis cell wall, inhibiting its growth.

Antimycobacterial Activity

We examined the in vitro antimycobacterial activities of the crude extract and the pure compounds isolated from it (1, 2, 3, 5, and 6) against the susceptible (H37Rv) and MDR-TB strains. The quantity of compound 4 obtained was enough for spectroscopic analyses only, but not enough for antimycobacterial activity.

In the preliminary sensitivity tests against both the susceptible (H37Rv) and MDR-TB strains, the results were based on the following classification: nonsensitive with a diameter < 8 mm; sensitive when diameter was from 9 to 14 mm; very sensitive when diameter ranged from 15 to 19 mm, and diameter > 20 mm was classified as extremely sensitive.22 Accordingly, the crude extract with zones of inhibition (diameter, 30 and 26 mm) at 50 mg/mL against the susceptible (H37Rv) TB strain and MDR-TB strain, respectively, was considered extremely sensitive against both strains (rifampicin 38.0 ± 0.0 mm against H37Rv strain; 0.00 against MDR strain).

The MIC values for both the susceptible (H37Rv) and MDR-TB strains are shown in Table 1. The activity of the extract against M. tuberculosis was classified using the following criteria: significant for MIC (μg/mL) < 100, moderate for MIC (μg/mL) 100 to 625, and weak or low for MIC (μg/mL) > 625.23 Meanwhile, the activity for a compound was classified as follows: significant for MIC (μg/mL) < 10, moderate for MIC (μg/mL) 10 to 100, and weak or low when MIC (μg/mL) > 100.23

From the antimycobacterial test results (Table 1), the activity (MIC 586 μg/mL) recorded for the crude extract was considered remarkable because it was moderately active against the susceptible strain of M. tuberculosis. This result justified the isolation of compounds from the crude extract to establish those responsible for the activity. Also, an earlier study by Bunalema et al had indicated a significant antimycobacterial activity of a Z. leptleriidii stem bark methanol extract. Furthermore, previous studies on extracts from some species of Zanthoxylum, such as Z. capense, Z. macrophylla, and Z. xanthocycloides, showed antimycobacterial activity.24,25

Considering the isolated compounds, the activity registered for compound 3 was the highest and most significant against the susceptible (H37Rv) strain (MIC 6 μg/mL), but only moderate against the MDR-TB strain (MIC 12.2 μg/mL). According to Abuzeid et al,26 this activity is comparable to the physiological concentration of rifampicin, currently used as a first-line treatment for TB. Also, we are reporting the antimycobacterial activity of compound 3 for the first time. Compound 2 showed moderate antimycobacterial activity against both the susceptible and MDR-TB strains (MIC 12.2 and 24.4 μg/mL, respectively) and was in line with an earlier report in which it had shown activity (MIC 25 μg/mL) when tested on the susceptible TB strain.24 Furthermore, compound 5 indicated a moderate activity against both the susceptible (H37Rv) and MDR-TB strains (MIC 48.8 and 98.0 μg/mL respectively), and this is the first report of its antimycobacterial activity. Compound 6 showed moderate activity against the susceptible (H37Rv) strain, but a weak activity against the MDR-TB strain (MIC 73.4 and 146.5 μg/mL, respectively). This study also reports for the first time the antimycobacterial activity of compound 6. In addition, compound 1 showed moderate activity (MIC 98.0 μg/mL) against H37Rv. This agrees with a previous report of it being active, in which it recorded a MIC of 100 μg/mL when tested on the susceptible (H37Rv) strain of M. tuberculosis.27 However, compound 1 showed weak activity (MIC 195.0 μg/mL) against MDR-TB. The results for the isolated compounds 2, 3, and 5 demonstrate their efficacies against both the susceptible (H37Rv) and MDR-TB strains. Thus, they could qualify as templates for new anti-TB drug development.

Generally, the antimycobacterial activity detected in the isolated compounds could be attributed to their lipophilic nature, which allows them to penetrate easily into the mycobacterial cell wall to hamper their growth.27 According to Brennan and Nikaido,28 M. tuberculosis is armed with lipid and waxed cell walls, making penetration very hard for most antibiotics and,
Figure 1. Structures of compounds 1, 2, 3, 4, 5, and 6 isolated from the stem bark of *Z. leprieurii*.
hence, a hard-to-treat organism. They are instead vulnerable to compounds that are less polar and having lipophilic properties. The lipophilicity of a drug molecule may enhance its ability to penetrate various biomembranes, subsequently improving its permeability into microbial cells.29

For compound 3 in particular, the significant antimycobacterial activity it exhibited could be attributable to the secondary amide linker in its structure, as shown in Figure 2. This assertion is supported by a previous report in which Yokokawa et al identified the secondary amide linker in their preliminary structure–activity relationship study while describing synthesizing tetrahydropyrimidine carboxamides as a vital pharmacophore essential for anti-TB activity. Another structure–activity relationship study of imidazo[1,2-a]pyridine amides also revealed that the secondary amide linker is critical for anti-TB activity.31 Furthermore, other studies have identified the secondary amide linker as a key pharmacophore responsible for anti-TB activity.32–34

It is worth noting that the secondary amide linker pharmacophore exists in the structures of rifampicin, isoniazid, and pyrazinamide, 3 of the 4 drugs used as first-line treatments for TB. In addition, amikacin and capreomycin, which are among the 4 second-line medicines for treating TB, contain this pharmacophore in their structures. In addition, a potent clinical drug candidate, Q203, which has shown excellent activity against the multidrug-resistant (MDR) and extensively drug-resistant strains of TB, contains the secondary amide linker in its structure.35 This relationship strongly supports the present study’s findings regarding the significant activity of compound 3. Also, it places it as a potential lead compound for developing effective TB drugs.

Biological activities of the isolated compounds have been reported in many previous studies. Compound 1 has anti-inflammatory, anticancer, antioxidant, and antimicrobial activities.36–38 Meanwhile, compound 2 has shown antihypertensive, antioxidant, anticancer, antiaging, and neuroprotective activities.39–40 Compound 3 has antiallergic, antifungal, antioxidant, antiplasmodial, and ovicidal properties.41–44 Camacho-Corona et al reported that compound 4 showed no antimycobacterial activity, but showed a slight antioxidant activity.45 Compound 5 exhibited a moderate antibacterial activity, as well as significant antiplasmodial and neuroprotective activities.47–48 Compound 6 has significant activities against allergy, hemorrhoids, hormonal disorders, cancer, and ulcers. Also, it has anti-inflammatory, anticonvulsant, analgesic, antibacterial, antifungal, antiviral, antioxidant, antifibrotic, hepatoprotective/nephroprotective, antidepressant, antiphotoaging, and free radical scavenger activities.49–55

Generally, medicinal plants are presumed to be harmless, although some of them possess toxic properties. Consequently, studies are normally conducted to establish their toxicity profiles to confirm that any biological activities observed from the plant extracts do not result from general metabolic toxic effects. Previous studies indicate that compounds 1, 3, and 5 isolated from this study have no cytotoxic activities.53,55 Compound 2 displayed a significant activity on cell lines of lung cancer, as well as ovarian and prostate cells. However, against normal lung epithelial cell lines, it showed no activity.57

Table 1. Mean MIC Values of the Crude Extract and Compounds 1 to 6 From the Stem Bark of Z. leprieurii on Different Strains of M. tuberculosis.

| Compounds | H37Rv ± SD | MDR ± SD |
|-----------|-----------|----------|
| Crude extract | 586.0 ± 275.8 | 1172.0 ± 552.9 |
| Compound 1 | 98.0 ± 0.0 | 195.0 ± 0.0 |
| Compound 2 | 12.2 ± 0.0 | 24.4 ± 0.0 |
| Compound 3 | 6.0 ± 0.0 | 12.2 ± 0.0 |
| Compound 4 | nd | nd |
| Compound 5 | 48.8 ± 0.0 | 98.0 ± 0.0 |
| Compound 6 | 73.4 ± 34.8 | 146.5 ± 0.0 |

1, lupeol; 2, sesamin; 3, trans-fagaramide; 4, arnottianamide; 5, (S)-marmesinin; 6, hesperidin; nd, not determined; SD, standard deviation; MICs, minimum inhibitory concentrations; MDR, multidrug resistant.

Conclusion

This is the first report of the isolation from the stem bark of Z. leprieurii of lupeol (1), sesamin (2), trans-fagaramide (3), arnottianamide (4), (S)-marmesinin (5), and hesperidin (6). Compound 3 has significant activity against the susceptible (H37Rv) strain of M. tuberculosis (MIC 6 μg/mL) and may present a vital template in pursuit of novel and highly effective TB drugs. Meanwhile, compounds 2, 5, 6, and 1 (MICs 12.2, 48.8, 73.4, and 98.0 μg/mL, respectively) have moderate activities against the susceptible (H37Rv) strain of M. tuberculosis. Also, all the tested compounds are active against the MDR-TB strain. The results of this study provide a scientific basis for the ethnopharmacological use of Z. leprieurii for the treatment of both susceptible and MDR forms of TB. Further studies to investigate the in vivo antimycobacterial activity and mode of action of compound 3, as well as the synergistic potential of the isolated compounds, would be valuable.
Experimental

General Experimental Procedures

Chromatography columns were packed with silica gel 60 (Merck; 70-230 mesh) and Sephadex LH-20 (Amersham Pharmacia Biotech AB) as stationary phases. Nuclear magnetic resonance spectra were measured on a Bruker Avance 500 MHz Spectrometer (Bruker Biospin). High-resolution mass spectra were obtained on an ESLQ-TOF Micro, 6200 Series Spectrometer (Agilent Technologies).

Plant Material

Zanthoxylum leprieurii (known locally as “Munyenyi” in Luganda) stem bark was collected from Mpaanga Forest Reserve in Mpigi district, Uganda (0.206032N, 32.300608E) in October 2018. Botanical identification was carried out by a taxonomist from Makerere University Herbarium and a voucher specimen No. OB 15 (with Plant Accession No. 50967) was deposited at the same Herbarium.

Extraction and Isolation

The air-dried and powdered stem bark (1000 g) was soaked in a chloroform/methanol (1:1, v/v) mixture for 24 h with occasional shaking. The extraction was repeated twice on the same sample to maximize extraction. The extract was filtered carefully, and the crude extract (94.25 g) was obtained upon concentration.

The extract (50 g) was loaded onto a silica gel packed column and eluted first with petroleum ether/ethyl acetate solvent mixture (100:0, 95:5, 90:10, 85:15, 80:20, 70:30, 60:40, 50:50, 30:70, 10:90, 0:100), followed by ethyl acetate/methanol solvent mixture (90:10, 80:20, 60:40). One hundred forty fractions (each 200 mL) were collected and combined in accordance to their TLC profiles to obtain eleven (11) main fractions labelled as AB, 2C, 2D, 2E, 2F, 2G, 2H, 2I, 2J, 2K, and 2L.

Fractions AB-2J were subjected separately to repetitive column chromatography employing silica gel as the stationary phase and using gradient elution to obtain the following pure compounds: 1 (56.0 mg) from Fraction 2C; 2 (110.5 mg) from Fraction 2E; 3 (125.6 mg) from Fraction 2G; and 4 (9 mg) from Fraction 2H. Also, Fractions 2K and 2L were subjected to repetitive column chromatography using gradient elution, and then on Sephadex using methanol/dichloromethane (1:1) to yield compounds: 5 (75.1 mg) and 6 (20 mg), respectively.

Antimycobacterial Activity

Mycobacterium tuberculosis strains and preparation of inoculums. A fully susceptible laboratory strain (H37Rv) and a known MDR TB (375) strain from a WHO Proficiency Testing panel were used as experimental mycobacterial strains. Both were obtained from the College of American Pathologists (CAP) ISO 15189 accredited Mycobacteriology Laboratory (BSL-3), College of Health Sciences, Makerere University.

Preserved strains of H37Rv and MDR TB were revived on Middlebrook 7H10 agar before the susceptibility tests.58,59 Cells crepted from freshly growing colonies (3 weeks old) were introduced into normal saline (10 mL). A bacterial suspension equivalent to 0.5 McFarland standard (1.5 × 10⁸ CFU) was prepared using a Sensititre Nephelometer by either adding more cells or diluting with more normal saline.59,60

Preparation of Plant Extracts and Compounds/Drugs. The dried crude extract (1000 mg) was dissolved in dimethyl sulfoxide (DMSO) (10 mL) to give a concentration of 100 mg/mL, and the extract was later sterilized using 0.2 μm single-use filters before use. A stock solution of rifampicin (1000 μg/mL) was diluted serially, and a working solution (100 μg/mL) was obtained.

Preparation of Bio Discs. Bio discs (diameter, 6 mm) were punched from a filter paper (Whatman No.1). They were sterilized at 121°C for 15 min and then impregnated with the extract/drug (20 μL) prepared earlier. The discs were dried in a hood for 12 h before use.

Procedure for Susceptibility Testing. Middlebrook 7H10 agar was used as the culture medium.60 The medium (20 mL) was poured into Petri dishes (diameter, 90 mm) with 4 quadrants such that each contained 5 mL of the medium. Then M. tuberculosis strain inoculums (100 μL) at 0.5 McFarland concentration were inoculated using a sterile single-use plastic loop on the solidified medium such that each quadrant contained 25 μL. An extract impregnated disc with a concentration of 50 mg/mL was placed in the first quadrant. A rifampicin impregnated disc containing 100 μg/mL was placed in the second quadrant. A blank disc and another disc impregnated with DMSO were placed in the third and fourth quadrants, respectively. The Petri dishes were left in the hood for 12 h before sealing them with micropore (carbon dioxide-permeable tape) to permit diffusion of the extract and drugs. After that, they were subjected to incubation in a carbon dioxide incubator running at 37°C for 21 days. Zones of inhibition (mm) that surrounded the discs were measured using a ruler to determine the sensitivity of M. tuberculosis strains to the extract and drugs.

Determination of MIC for Crude Extract. MIC was determined using the macro broth dilution method by diluting the extract serially in Middlebrook 7H9 medium.61,62 The medium (5 mL) was dispensed into a 15 mL Falcon tube before adding an equal volume of the extract at a 50 mg/mL concentration. A 20-fold dilution was made by mixing the extract with the medium 6 times before pipetting off 5 mL to the next tube containing 7H9 medium (5 mL) until a final concentration (0.1 μg/mL) was obtained. The extract was inoculated with 0.5 mL of 0.5 McFarland of H37Rv and MDR strains. The tubes were left in the incubator shaker at 37°C for 14 days. The MIC was the lowest concentration having no visible growth, as indicated by clog formation of M. tuberculosis cells
on the macro broth tube wall. The tests were made in duplicates. DMSO was used as a negative control.

**Determination of MIC for Isolated Compounds.** The activities of the compounds against susceptible (H37Rv) and MDR TB strains were tested following the microplate Alamar blue assay. Sterile distilled water (200 μL) was added to all outer perimeter wells of sterile 96-well plates to minimize evaporation. The remaining wells received 100 μL of 7H9 broth. Double concentration drug solutions (100 μL) were added to each of the wells in rows B to G in column 2, and 2-fold serial dilutions were made through column 10 using a multichannel pipette. All the wells in columns 2 to 11 were inoculated with 100 μL of *M. tuberculosis*, bringing the final volume to 200 μL per well. The plates were incubated at 37°C for 21 days. Freshly prepared Alamar blue reagent (30 μL) was later added to one of the control wells and incubated at 37°C for 24 h. Observation of a color change indicated that there was growth. The dye was later added to all the wells and further incubated for 24 h. The MIC of the isolated compounds was then determined. Standard drugs: rifampicin and isoniazid were used as positive controls. The tests were prepared in triplicate for each of the strains used. The bioassays were performed in a Mycobacteriology Laboratory (BSL-3).

**Acknowledgments**

The authors thank the following sincerely: Mr Peter Nelson Sekandi from the Department of Chemistry, College of Natural Sciences, Makerere University and Mr George Kwegyira from the Institute of Chemistry, University of Potsdam, Germany, for their technical support during the isolation of the compounds; Ms Angela Kritschka and Ms Sylvia Fürstenberg both from the Institute of Chemistry, University of Potsdam, Germany for carrying out spectroscopic analyses of the compounds; and Mr Kevin Komakech from the Mycobacteriology Laboratory (BSL-3) at the College of Health Sciences, Makerere University, for carrying out the antimycobacterial assay.

Also, the authors acknowledge valuable support to Benson Oloya through the attendance of a Summer School on “Separation and structure elucidation of phytochemicals” for 2 months hosted at Egerton University, Kenya, by the Phytochem Project. The project was funded by the DAAD and the German Ministry of Education and Research (BMBF) under the "Partnership for Sustainable Solution in Sub-Saharan Africa," Grant no. SSA2015 to 33 to 074.

**Declaration of Conflicting Interests**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Deutscher Akademischer Austauschdienst (DAAD) In-Country Scholarship, Uganda 2016 (through a DAAD PhD Scholarship and a DAAD Short Term Research Travel Grant to Benson Oloya, Personal no. 91560246).

The authors gratefully acknowledge the DAAD for funding this study.

**Supplemental Material**

Supplemental material for this article is available online.

**ORCID iD**

Benson Oloya https://orcid.org/0000-0003-0874-0380

**References**

1. WHO. Global Tuberculosis Report. 2020.
2. Paul GF, Case RJ, Inui T, et al. New perspectives on natural products in TB drug research. *Life Sci*. 2005;78(5):485–494. doi:10.1016/j.lfs.2005.09.004
3. Bunalema L, Obakiro S, Tabutti JRS, Waako P. Knowledge on plants used traditionally in the treatment of tuberculosis in Uganda. *J Ethnopharmacol*. 2014;151(2):999–1004. doi:10.1016/j.jep.2013.12.020
4. Fotie J, Bohle DS, Leimani ML, Georges E, Rukunga G, Nkengfack AE. Lupenol long-chain fatty acid esters with antimalarial activity from *Hedarrhena floribunda*. *J Nat Prod*. 2006;69(1):62–67.
5. Ahmad VU, Bano S, Mohammad FV. Nepethin—A new triterpene from *Nepeta hindoostana*. *Planta Med*. 1985;51(6):521–523. doi:10.1055/s-0037-969582
6. Takeya T, Ara Y, Tobinaga S. Reactions of lignan precursors, cinnamyl alcohols and cinnamic acids, with Weitz’ amonium salt. *Chem Pharm Bull (Tokyo)*. 1995;43(11):1970–1976.
7. Moussavi N, Malterud KE, Mikolo B, et al. Identification of chemical constituents of *Zanthoxylum bietzii* stem bark and their insecticidal activity against the malaria mosquito *Anopheles gambiae*. *Parasit Vectors*. 2015;8(1):1–8. doi:10.1186/s13071-015-1113-x
8. Cheng M, Yang C-H, Lin W-Y, Lin W, Tsai I-L, Chen I-S. Chemical constituents from the leaves of *Zambouyym schinifolium*. *J Chinese Chem Soc*. 2002;49(1):125–128. doi:10.1002/jccs.200200021
9. Correa EA, Högestätt ED, Sterner O, Echeverri F, Zygmunt PM. In vitro TRPV1 activity of piperine derived amides. *Bioorg Med Chem*. 2010;18(9):3299–3306. doi:10.1016/j.bmc.2010.03.013
10. Ng KM, Gray AI, Waterman PG, But PP, Kong Y-C. Limonoids, alkaloids, and a coumarin from the root and stem barks of *Tetradium glabriolium*. *J Nat Prod*. 1987;50(6):1160–1163.
11. Talontsi FM, Matasyoh JC, Ngoumfo RM, Chepkorir R. Mosquito larvicidal activity from *Zambouyym schinifolium* leaves against the malaria vector *Anopheles gambiae*. *Pestic Biochem Physiol*. 2013.12.020
12. Lee S, Shin D, Kim JS, Oh K, Kang SS. Antibacterial coumarins from *Angelica gigas* roots. *Arch Pharm Res*. 2003;26(6):449–452.
13. Nizamuddinova IT, Jeong JJ, Xu GH, et al. Hesperidin, hesperidin methyl chalone and phellopterin from *Poncirus trifoliata* (Rutaceae) differentially regulate the expression of adhesion molecules in tumor necrosis factor-α-stimulated human umbilical vein
endothelial cells. *Int Immunopharmacol*. 2008;8(5):670–678. doi:10.1016/j.intimp.2008.01.011

14. Waterman PG, Gray AI, Crichton EG. A comparative study on the alkaloids of *Zanthoxylum leptocladus*, *Z. leumairei* and *Z. rubescens* from Ghana. *Biochem Syst Ecol*. 1976;4(4):259–262. doi:10.1016/0305-0787(76)90049-1

15. Omosa LK, Okemwa EK. Antiplasmodial activities of the stem bark extract and compounds of *Zanthoxylum gilletii* (de wild) P.G. Waterman. *Pharmacogn Commun*. 2017;7(1):41–46. doi:10.5530/pc.2017.1.6

16. Adesina SK. Amottamianide and other constituents of *Zanthoxylum gilletii* roots. *J Nat Prod*. 1988;51(3):601–602.

17. Pauline N, Cabral BNP, Anatole PC, Jocelyne AMV, Bruno M, Jeanne NY. The in vitro antisinglic and antioxidant effects of aqueous extracts *Zanthoxylum heitzii* on sickle cell disorder. *BMC Complement Altern Med*. 2013;13(162):1–7.

18. Bunalema L, Fotso GW, Waako P, Tabuti J, Yeboah SO. Potential of *Zanthoxylum leptocladus* as a source of active compounds against drug resistant *Mycobacterium tuberculosis*. *BMC Complement Altern Med*. 2017;17(1):4–9. doi:10.1186/s12906-017-1602-x

19. Cowan MM. Plant products as antimicrobial agents. *Clin Microbiol Rev*. 1999;12(4):564–582.

20. Parekh J, Jadeja D, Chanda S. Efficacy of aqueous and methanol extracts of some medicinal plants for potential antibacterial activity. *Turkish J Biol*. 2005;29(4):203–210. http://journals.tubitak.gov.tr/biology/issues/biy-05-29-4/biy-29-4-3-0506-4.pdf

21. Kumar A, Ilavarasan R, Jayachandran T, et al. Phytochemical investigation on a tropical plant, *Syzygium cumini* from Katruppayalam, Erode district, Tamilnadu, South India. *Pakistan J Nutr*. 2009;8(1):83–85. doi:10.3923/pjn.2009.83.85

22. Ponce AG, Fritz R, Del Valle C, Roura SI. Antimicrobial activity of essential oils on the native microflora of organic Swiss chard. *LWT - Food Sci Technol*. 2003;36(7):679–684. doi:10.1016/S0023-6438(03)00088-4

23. Kuete V. Potential of Cameroonian plants and derived products against microbial infections: a review. *Planta Med*. 2010;76(14):1479–1491. doi:10.1055/s-0030-1250027

24. Luo X, Pires D, Ainsa JA, et al. *Zanthoxylum capense* constituents with antimycobacterial activity against *Mycobacterium tuberculosis* in vitro and ex vivo within human macrophages. *J Ethnopharmacol*. 2013;146(1):417–422. doi:10.1016/j.jep.2013.01.013

25. Tekwu EM, Askun T, Kuete V, et al. Antibacterial activity of selected Cameroonian dietary spices ethno-medically used against strains of *Mycobacterium tuberculosis*. *J Ethnopharmacol*. 2012;142(2):374–382. doi:10.1016/j.jep.2012.05.003

26. Abuzeid N, Kalsum S, Koshy RJ, et al. Antimycobacterial activity of selected medicinal plants traditionally used in Sudan to treat infectious diseases. *J Ethnopharmacol*. 2014;157(November):134–139. doi:10.1016/j.jep.2014.09.020

27. Bibi N, Tanoli SAK, Farheen S, et al. In vitro antituberculosis activities of the constituents isolated from *Haloxylon salicornicum*. *Bioorganic Med Chem Lett*. 2010;20(14):4173–4176. doi:10.1016/j.bmcl.2010.05.061

28. Brennan PJ, Nikaido H. The envelope of mycobacteria. *Annu Rev Biochem*. 1995;64(3):29–63. doi:10.1146/annurev.bi.64.070195.000333

29. Mashooq AB. Synthesis and antymycobacterial activity of new 4-thiazolidinone and 1, 3, 4-oxadiazole derivatives of isoniazid. *Acta Pol Pharm*. 2014;71(5):763–770.

30. Yokokawa F, Wang G, Chan WL, et al. Discovery of tetrahydropyrrolopyrimidinone carboxamide derivatives as potent and orally active antituberculosis agents. *ACS Med Chem Lett*. 2013;4(5):451–455.

31. Kang S, Kim RY, Seo MJ, et al. Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug resistant antituberculosis agent. *J Med Chem*. Published online 2014:57(12):5293–5305. doi:10.1021/jm503606

32. Ollinger J, Bailey MA, Moraski GC, et al. A dual read-out assay to evaluate the potency of compounds active against *Mycobacterium tuberculosis*. *PLoS One*. 2013;8(4):1–9. doi:10.1371/journal.pone.0060531

33. Moraski GC, Markley LD, Hipkiss PA, et al. Advent of imidazo[1,2-a]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity. *ACS Med Chem Lett*. 2011;2(6):466–470. https://doi.org/10.1021/ml200036r

34. Onajole OK, Lun S, Yun VJ, et al. Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyridinecarboxamides as potent antituberculosis agents. *Chem Biol Drug Des*. 2020;96(6):1362–1371. doi:10.1111/cbd.13739

35. Pethe K, Bifani P, Jang J, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. *Nat Med*. 2013;19(9):1157–1160. doi:10.1038/nm.3262

36. Ahmad SF, Pandey A, Kour K, Bani S. Downregulation of pro-inflammatory cytokines by lupeol measured using cytometric bead array immunoassay. *Phytomer. 2010;24(1):9–13. doi:10.1002/ptr

37. Liu K, Zhang X, Xie L, et al. Lupeol and its derivatives as anticancer and anti-inflammatory agents: molecular mechanisms and therapeutic efficacy. *Pharmaco Res*. 2021;164 (February):1–73. doi:10.1016/j.phrs.2020.105373

38. Min T-R, Park H-J, Ha K-T, Choi G-Y, Choi Y-H, Park S-H. Suppression of EGFR/STAT3 activity by lupeol contributes to the induction of the apoptosis of human non-small cell lung cancer cells. *Int J Oncol*. 2019;55(1):320–330. doi:10.3892/ijo.2019.4799

39. Udomruk S, Kaewmool C, Pothacharoen P, Phitak T, Kongtawelert P. Sesamin suppresses LPS-induced microglial activity via regulation of TLR4 expression. *J Fungi Foods*. 2018;4(8):32–43. doi:10.3892/jff.2018.08020

40. Wu M-S, Aquino LBB, Barbaza MYU, et al. Anti-inflammatory and anticancer properties of bioactive compounds from *Sesamum indicum* L.—A review. *Molecules*. 2019;24(24):1–28. doi:10.3390/molecules24244426

ADIA MM, EMAMI SN, BYAMUKAMA R, FAYE J, BORG-KARLSSON AK. Antiplasmodial activity and phytochemical analysis of extracts from selected Ugandan medicinal plants. *J Ethnopharmacol*. 2016;186(March):14–19. doi:10.1016/j.jep.2016.03.047
53. Lee CJ, Queiroz EF, Ndjoko K, Diallo D, Hostettmann K. Antifungal and antioxidant compounds from the root bark of Fagara zanthoxyloides. *Planta Med.* 2003;69(4):316–320. doi:10.1055/s-2003-38877

54. Kumar A, Lalitha S, Mishra J. Hesperidin potentiates the neuroprotective effects of diazepam and gabapentin against pentylenetetrazole-induced convulsions in mice: possible behavioral, biochemical and mitochondrial alterations. *Pharmacol Rep.* 2011;63(9):714–719. doi:10.2478/s11102-011-0297-7

55. Mbaveng AT, Damen F, Çelik İ, Tane P, Kuete V, Efferth T. Cytoxicity of the crude extract and constituents of the bark of Fagara tesmimaniens towards multi-drug resistant cancer cells. *J Ethnopharmacol.* 2019;235(January):28–37. doi:10.1016/j.jep.2019.01.031

56. He R, Zhang Y, Wu L, et al. Benzofuran glycosides and coumarins from the bark of *Streblus indicus* (Bur.) Corner. *Phytochem* 2017;138(June):170–177. doi:10.1016/j.phytochem.2017.01.011

57. Salas F, Rojas J, Morales A, Ramos-Nino ME, Colmenares NG. In vitro cytotoxic activity of sesamin isolated from *Vismia bacifera* var. *Deadvata triana* & planch (guttiferae) collected from Venezuela. *Nat Prod Commun.* 2008;3(10):1705–1708. doi:10.1177/19345780800301025

58. Mohamad S, Zin NM, Wahab HA, et al. Antituberculosis potential of some ethnobotanically selected Malaysian plants. *J Ethnopharmacol.* 2011;133(3):1021–1026. doi:10.1016/j.jep.2010.11.037

59. Sanders CA, Nieda RR, Desmond EP. Validation of the use of middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of *Mycobacterium tuberculosis* to levofloxacin. *J Clin Microbiol.* 2004;42(11):5225–5228. doi:10.1128/JCM.42.11.5225-5228.2004

60. Komakech K, Kateregga J, Namaganda C, Semugenze D, Lubega A. In vitro anti-tuberculosis activity of total crude extract of *Echiopsis amplexicaulis* against multi-drug resistant *Mycobacterium tuberculosis*. *J Heal Sci.* 2018;6:296–303. doi:10.17265/2328-7136/2018.04.008

61. CLSI. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard, CLSI Document M07-A9.* Vol 32. 9th ed. Clinical and Laboratory Standards Institute, 950; 2012,32(2):16-40.

62. The National Institute of Open Schooling. “Antibiotic susceptibility test: module microbiology, lesson 12.” The National Institute of Open Schooling (NIOS) Government of India. Published 2012. http://www.nios.ac.in/media/documents/dme/landscape%0A/Victim%20s12906-017-2058-8

63. Lawal TO, Adeniyi BA, Wan B, Franzblau SG, Mahady GB. In-vitro susceptibility of *Mycobacterium tuberculosis* to extracts of *Uvaria afzelii* Scott Elliot and *Tetraera anfihila* Willd. *African J Biomed Res.* 2011;14(1):17–21.